Iluvien, a sustained release drug-delivery system for the treatment of diabetic macular edema, may be getting closer to possible FDA approval. The parent company, Alimera Sciences has resubmitted additional safety and efficacy data as requested by the FDA last year. …
Category: Retina
Stem Cells in Ophthalmology Update 7: Research Studies with Induced Pluripotent Stem Cells Suggest Opposite Results
Two research studies were published this week, about the use of induced pluripotent stem cells (iPSCs) in treating retinal problems, but with opposing results. In one study, published in Nature, Dr.Yang Xu and his colleagues at the University of California,…
Avastin and Lucentis Are Equally Safe, Too.
CATT trial revealed that it appears Avastin is as effective as Lucentis for the treatment of wet ARMD. They are equally safe, too.
Avastin Just as Good as Lucentis
It’s official. Avastin is just as good as Lucentis for the treatment of wet macular degeneration. The results of this National Eye Institute study were released just a week ago. The study, Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)…
CATT Update 15: Preliminary Two-Year Safety Data Presented at ARVO
Two of the authors of the CATT Study, that was published in the NEJM last Thursday, Drs. Dan Martin and Maureen McGovern, presented additional information about the study at the opening day ARVO Meeting, to about 2000 eager attendees. As…
Laser and anti-VEGF Best Treats Diabetic Macular Edema
A new study finds the combination of laser treatment with intraocular injections of anti-VEGF to be the best treatment for diabetic retinopathy.
VEGF-Trap Gets Closer to FDA Approval
VEGF-Trap (aka aflibercept), another anti-VEGF drug, moves closer to FDA approval as it received priority review status. This status means that the FDA process will be accelerated and the drug can be reviewed in 6 months versus the usual 10…
Promedior Announces Presentation Of Data At ARVO Demonstrating That PRM-151 (rhPTX-2) Suppresses Choroidal And Retinal Neovascularization
Promedior, Inc. today announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)… Full Story →
Annual Eye Exams Not Cost-Effective For People With Diabetes And At Low Risk Of Diabetic Retinopathy Progression
Eye examinations every other year are more cost-effective than currently recommended annual eye exams for people with diabetes who are at low risk of diabetic retinopathy progression…
Neurotech’s NT-501 Implant Demonstrates Statistically Significant Photoreceptor Preservation In Patients With Retinal Degenerative Disease
Neurotech Pharmaceuticals, Inc., today announced that, as reported in Investigative Ophthalmology & Visual Science (April, 2011, Vol…
Neurotech’s NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy Associated with Dry AMD as Reported in PNAS
LINCOLN, R.I.–(BUSINESS WIRE)–Neurotech announced that it was reported in PNAS that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy associated with dry AMD in a Phase 2 study. Full Story →
Eating Fish and Omega-3′s Lower ARMD Risk in Women
A new study indicates that eating one serving of fish per week may prevent macular degeneration in women!
Lucentis Approved in Europe to Treat Patients With Macular Edema Secondary to Retinal Vein Occlusion
Novartis announced Friday that it had received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients in the European Union with visual impairment due to macular edema secondary to retinal vein occlusion (RVO). Lucentis was shown to improve vision and vision related quality of life […]
Stem Cells in Ophthalmology Update 6: Stemedica Paper Accepted for Presentation at ARVO
I recently received an update from my contact at Stemedica and would like to share the information with you. A safety study on the use of stem cells in the eye, in a clinical study underway at the Fyodorov Federal Institution of Eye Microsurgery …
RETINAWS 2010
RETINAWS was presented on Saturday evening,
May 1, 2010, in the Fort Lauderdale Convention
Center. Below you will find a brief description of
cases presented. RETINAWS was recorded live
and can be watched on www.eyetube.net/Retinaws. We
would like to t…
Standing Inside the Eye
Retina Today eminterviewed Szilárd Kiss, MD, of Weill
Cornell Medical College to learn about how an interactive,
3-D virtual reality technology, is being used to better
understand disease processes in the eye./em
h3Q: What is the CAVE?/h3
Szilárd Kis…
Diabetic Macular Edema: Have No Fear
Diabetic macular edema occurs in virtually every patient with diabetes. It is the most common “complication” of diabetic retinopathy. Treatment is safe, painless and effective.
Avastin/Lucentis Update 45: Avastin Drug Treatment of ROP Better than Laser
A new study, published earlier this month in the New England Journal of Medicine, describes the use of intravitreal Avastin to treat Retinopathy of Prematurity (ROP) in premature infants. This study was widely covered by the press, but I would…
Me, My Dog and…Social Media
Are You Part of the Conversation? Man’s best friend? Absolutely, for me, my best friend’s name is Keno. She has been by my side through my divorce, raising three children on my own, my remarriage, the integration of my blended family and has rightfully earned a place in my heart and in our family. Lost […]
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic m…